Literature DB >> 29382641

First WHO antimicrobial surveillance data reveal high levels of resistance globally.

Susan Mayor1.   

Abstract

Year:  2018        PMID: 29382641     DOI: 10.1136/bmj.k462

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis.

Authors:  Yukiko Ezure; Veronica Rico; David L Paterson; Lisa Hall; Patrick N A Harris; Alex Soriano; Jason A Roberts; Matteo Bassetti; Matthew J Roberts; Elda Righi; Hugh Wright
Journal:  Open Forum Infect Dis       Date:  2020-10-10       Impact factor: 4.423

2.  Rapid MinION profiling of preterm microbiota and antimicrobial-resistant pathogens.

Authors:  Richard M Leggett; Cristina Alcon-Giner; Darren Heavens; Shabhonam Caim; Thomas C Brook; Magdalena Kujawska; Samuel Martin; Ned Peel; Holly Acford-Palmer; Lesley Hoyles; Paul Clarke; Lindsay J Hall; Matthew D Clark
Journal:  Nat Microbiol       Date:  2019-12-16       Impact factor: 17.745

Review 3.  Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture.

Authors:  Pascale Salameh; Christine Roques; Katia Iskandar; Laurent Molinier; Souheil Hallit; Massimo Sartelli; Timothy Craig Hardcastle; Mainul Haque; Halyna Lugova; Sameer Dhingra; Paras Sharma; Salequl Islam; Irfan Mohammed; Isa Naina Mohamed; Pierre Abi Hanna; Said El Hajj; Nurul Adilla Hayat Jamaluddin
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-31       Impact factor: 4.887

4.  In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.

Authors:  Peiyao Jia; Ying Zhu; Hui Zhang; Bin Cheng; Ping Guo; Yingchun Xu; Qiwen Yang
Journal:  BMC Microbiol       Date:  2022-10-01       Impact factor: 4.465

5.  Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis.

Authors:  Syeda Sahra; Abdullah Jahangir; Rachelle Hamadi; Ahmad Jahangir; Allison Glaser
Journal:  Infect Chemother       Date:  2021-06

6.  Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016).

Authors:  Hui Zhang; Yingchun Xu; Peiyao Jia; Ying Zhu; Ge Zhang; Jingjia Zhang; Simeng Duan; Wei Kang; Tong Wang; Ran Jing; Jingwei Cheng; Yali Liu; Qiwen Yang
Journal:  Antimicrob Resist Infect Control       Date:  2020-10-27       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.